Related Experiment Video

Updated: Jul 10, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor

Jitesh P Jani1, Richard S Finn, Mary Campbell

  • 1Department of Cancer Discovery, Pfizer Global Research and Development, Groton, Connecticut 06340, USA.

Cancer Research
|October 19, 2007
PubMed

Insights

CP-724,714 effectively inhibits HER2-driven breast cancer growth by blocking erbB2 autophosphorylation and inducing apoptosis. This orally available small-molecule inhibitor shows promise in preclinical models with minimal adverse effects.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Amplification and overexpression of the erbB2 (Her-2/neu) proto-oncogene are implicated in various human cancers, including breast, ovarian, and stomach tumors.
  • Overexpression of erbB2 affects tumor growth, chemotherapy sensitivity, patient prognosis, and disease-free survival.
  • While trastuzumab (Herceptin) improves survival in HER2-positive breast cancer, there's a need for potent, orally bioavailable small-molecule inhibitors.

Purpose of the Study:

  • To investigate the in vitro and in vivo effects of CP-724,714, a novel erbB2 inhibitor, in human breast cancer models.
  • To evaluate the selectivity and mechanism of action of CP-724,714 in HER2-driven cancer cells.
  • To assess the efficacy and safety of orally administered CP-724,714 in preclinical breast cancer xenograft models.

Main Methods:

  • In vitro studies using HER2-driven and non-HER2-driven cell lines to assess growth inhibition and cell cycle effects.
  • In vivo studies involving oral administration of CP-724,714 to athymic mice bearing erbB2-overexpressing human breast cancer xenografts.
  • Analysis of molecular markers including erbB2 autophosphorylation, extracellular signal-regulated kinase (ERK) and Akt phosphorylation, and caspase-3 activation.

Main Results:

  • CP-724,714 demonstrated selectivity, inhibiting the growth of HER2-driven cell lines.
  • The compound induced a G1 cell cycle block in BT-474 human breast carcinoma cells and inhibited erbB2 autophosphorylation in vivo.
  • Oral administration of CP-724,714 led to reduced ERK and Akt phosphorylation, increased tumor cell apoptosis, and caspase-3 release, inhibiting tumor growth without significant adverse effects.

Conclusions:

  • CP-724,714 is a potent and selective inhibitor of erbB2 signaling with promising anti-cancer activity in preclinical breast cancer models.
  • The drug's ability to inhibit erbB2 autophosphorylation, induce cell cycle arrest, promote apoptosis, and its oral bioavailability make it a potential therapeutic candidate.
  • CP-724,714 warrants further clinical investigation as a targeted therapy for HER2-overexpressing cancers.

More Related Videos

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...